- Home
- CVM
CVM
Cel-Sci Corporation
as 03-31-2025 9:49am EST
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | VIENNA |
| Market Cap: | N/A | IPO Year: | 1987 |
| Target Price: | N/A | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.23 - $2.39 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cel-Sci Corporation News
CVM Breaking Stock News: Dive into CVM Ticker-Specific Updates for Smart Investing
Business Wire
7 days ago
CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients
Business Wire
13 days ago
CEL-SCI Announces Closing of $2.5 Million Offering
Business Wire
14 days ago
CEL-SCI Announces Pricing of $2.5 Million Offering
Business Wire
14 days ago
CEL-SCI’s Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
Business Wire
17 days ago
Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCI’s Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression
Business Wire
a month ago
CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial
Business Wire
a month ago
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
Associated Press Finance
a month ago
Cel-Sci: Fiscal Q1 Earnings Snapshot
Compare CVM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CVM Cel-Sci Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.